Many of the early clinical successes using intravenous transplantation came in systemic diseases such as graft versus host disease and sepsis. Direct injection or placement of cells into a site in need of repair may be the preferred method of treatment, as vascular delivery suffers from a "pulmonary first pass effect" where intravenous injected cells are sequestered in the lungs.
Gabriel Rada, Javiera Corbalan, et al. Mesenchymal stromal cells for COVID-19: A living systematic review protocol. DOI: 10.1101/2020.04.13.20064162.
2020 Apr 13. DOI: 10.1007/s12015-020-09973-w.Stem Cells Dev.
Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. DOI: 10.1101/2020.04.08.20057794., ,et al.
2020 Apr 9;9(4):E924. DOI: 10.3390/cells9040924.Cell.
Eur Respir J. 2020 Apr 7;2000858. DOI: 10.1183/13993003.00858-2020.
Pain Physician. 2020 Mar;23(2):E71-E83.
Ashok K Shetty. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia. Aging Dis. 2020 Mar 9;11(2):462-464. DOI: 10.14336/AD.2020.0301.
Aging Dis. 2020 Mar 9;11(2):216-228. DOI: 10.14336/AD.2020.0228.
Engineering (Beijing). 2020 Feb 28. DOI: 10.1016/j.eng.2020.02.006.